Bär & Karrer advises the managers in CHF 18.6 million rights offering of Kuros Biosciences
Kuros Biosciences, a life science company focusing on the development and marketing of orthobiologics, completed a capital increase by way of a rights offering to its shareholders. 50.2% of the shareholders of Kuros Biosciences exercised their subscription rights in the rights offering. The remaining 4,192,530 offered shares were placed in the market and an additional tranche of 1,915,203 shares was sold to Optiverder B.V. The offer price was set at CHF 1.80 per share.